Tianjin Medical University — Biomedical Watch V2

Traitements12programmes

Essais6liés

Publications1liées

SourceDBlocale

Traitements

12

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis\[18F\]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene (\[18F\]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid. By comparing its diagnostic performance against established clinical methods, including echocardiography, contrast-enhanced MRI, and relevant laboratory tests, this study aims to establish \[18F\]FT8 as the basis for a robust PET protocol for the direct visualization and differential diagnosis of AL amyloidosis . The study preimarily evaluates the safety and diagnostic efficacy of \[18F\]FT8 PET imaging in human subjects.	Alzheimer	À vérifier	À vérifier	China	À vérifier
[18F]NIDF PET Imaging in Tau-related DiseasesIn the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents. This clinical research project aims to visualize abnormal tau pathology in the living human brain using \[18F\]NIDF PET imaging. \[18F\]NIDF is a 2-arene-azaindole-based tracer that offers stronger binding affinity to tau neurofibrillary tangles and reduced non-specific/off-target binding compared to existing tau-PET imaging agents. The study primarily focuses on evaluating the safety and diagnostic efficacy of \[18F\]NIDF PET imaging in human subjects.	Alzheimer	À vérifier	À vérifier	China	À vérifier
Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseTo evaluate the potential usefulness of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various α-Syn-related disease patients.	Parkinson	À vérifier	À vérifier	China	À vérifier
Beta Amyloid PET/CT in Various Aβ-Related DiseaseTo evaluate the potential usefulness of 18F-92/AV45, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.	Alzheimer	À vérifier	À vérifier	China	À vérifier
Monoamine Oxidase B PET/CT in Various MAO-B-Related DiseaseTo evaluate the potential usefulness of 18F-FPyCO/SMBT-1 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-B-related disease patients.	Parkinson	À vérifier	À vérifier	China	À vérifier
Pan-Amyloid PET/CT in Various Amyloid-Related DiseaseTo evaluate the potential usefulness of 18F-92/AV45/TPZA/FT8, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Pan-Amyloid-related disease patients.	Alzheimer	À vérifier	À vérifier	China	À vérifier
Monoamine Oxidase B PET/CT in Various MAO-B-Related DiseaseTo evaluate the potential usefulness of 18F-FPyCO/SMBT-1 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-B-related disease patients.	Parkinson	À vérifier	À vérifier	China	À vérifier
Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseTo evaluate the potential usefulness of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various α-Syn-related disease patients.	Parkinson	À vérifier	À vérifier	China	À vérifier
[18F]NIDF PET Imaging in Tau-related DiseasesIn the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents. This clinical research project aims to visualize abnormal tau pathology in the living human brain using \[18F\]NIDF PET imaging. \[18F\]NIDF is a 2-arene-azaindole-based tracer that offers stronger binding affinity to tau neurofibrillary tangles and reduced non-specific/off-target binding compared to existing tau-PET imaging agents. The study primarily focuses on evaluating the safety and diagnostic efficacy of \[18F\]NIDF PET imaging in human subjects.	Alzheimer	À vérifier	À vérifier	China	À vérifier
Pan-Amyloid PET/CT in Various Amyloid-Related DiseaseTo evaluate the potential usefulness of 18F-92/AV45/TPZA/FT8, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Pan-Amyloid-related disease patients.	Alzheimer	À vérifier	À vérifier	China	À vérifier
Beta Amyloid PET/CT in Various Aβ-Related DiseaseTo evaluate the potential usefulness of 18F-92/AV45, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.	Alzheimer	À vérifier	À vérifier	China	À vérifier
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis\[18F\]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene (\[18F\]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid. By comparing its diagnostic performance against established clinical methods, including echocardiography, contrast-enhanced MRI, and relevant laboratory tests, this study aims to establish \[18F\]FT8 as the basis for a robust PET protocol for the direct visualization and differential diagnosis of AL amyloidosis . The study preimarily evaluates the safety and diagnostic efficacy of \[18F\]FT8 PET imaging in human subjects.	Alzheimer	À vérifier	À vérifier	China	À vérifier

Essais cliniques

6

Molécule	Indication / population	Phase	NCT	Titre	Statut
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis	Alzheimer	À vérifier	NCT07232459	[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis	RECRUITING
Beta Amyloid PET/CT in Various Aβ-Related Disease	Alzheimer	À vérifier	NCT06725706	Beta Amyloid PET/CT in Various Aβ-Related Disease	RECRUITING
Pan-Amyloid PET/CT in Various Amyloid-Related Disease	Alzheimer	À vérifier	NCT07130565	Pan-Amyloid PET/CT in Various Amyloid-Related Disease	RECRUITING
[18F]NIDF PET Imaging in Tau-related Diseases	Alzheimer	À vérifier	NCT07306598	[18F]NIDF PET Imaging in Tau-related Diseases	RECRUITING
Alpha-Synuclein PET/CT in Various α-Syn-Related Disease	Parkinson	À vérifier	NCT06949670	Alpha-Synuclein PET/CT in Various α-Syn-Related Disease	RECRUITING
Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease	Parkinson	À vérifier	NCT07685873	Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease	RECRUITING

Publications

1

Molécule	Indication / population	Titre	Journal	Date
Beta Amyloid PET/CT in Various Aβ-Related Disease		Early Detection of Amyloid-Related Changes in Memory among Cognitively Unimpaired Older Adults with Daily Digital Testing.	Annals of neurology